Data from the phase 3 KEYNOTE-604 trial showed that patients with extensive-stage small cell lung cancer (ES-SCLC) who received pembrolizumab with backbone chemotherapy etoposide/platinum (EP) compared with patients who received EP and placebo did not benefit from improved overall survival (OS). However, progression-free survival (PFS) rates did reach the threshold for significance.
Dr Charles M. Rudin (Memorial Sloan Kettering Cancer Center, USA) presented the findings . The KEYNOTE-604 study aimed to improve upon the efficacy of immunotherapy in newly diagnosed ES-SCLC with the combination of pembrolizumab and EP.
The study randomised 453 patients; pembrolizumab 220 mg on day 1 plus EP 100 mg/m2 on days 1 and 2 and carboplatin AUC 5 on day 1 or cisplatin 75 mg/m2 on day 1 (n=228) or placebo, matching EP, and carboplatin or cisplatin (n=225) for up to 31 cycles. The co-prim...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Prostate cancer: ARAMIS, SPARTAN, and PROSPER Next Article
HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.